Status: Not yet recruiting
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
Participants needed: 424
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Oct 5, 2026Locations: 7
Eligibility criteria
Documented locally advanced or metastatic solid tumor(s) not amenable to curativ... [+3]
Chemotherapy, biological therapy, immunotherapy, targeted therapy (including sma... [+21]